Work

Supplementary Tables S1-S3 from Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Tables S1-S3. Table S1: The complete dose escalation schema for ADI-PEG 20 in combination with docetaxel. Table S2: Details the completed pharmacodynamic data for individual patients. Includes concentrations of arginine and citrulline over time and the titers of antibodies to ADI-PEG 20. Table S3: Highlights response against tumor type in patients where response was able to be assessed.

DOI: 10.1158/1078-0432.22458221.v1

Authors: Benjamin K. Tomlinson, James A. Thomson, John S. Bomalaski, Monica Diaz, Taiwo Akande, Nichole Mahaffey, Tianhong Li, Mrinal P. Dutia, Karen Kelly, I-Yeh Gong, Thomas Semrad, David R. Gandara, Chong-Xian Pan, Primo N. Lara

Language: English

Topic: Cancer Research and Treatments

Subfield: Biotechnology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361916598

Cites:

Cited by:

Related to: 10